Advent warms CoCo

On the heels of data published last month from the lab of Jonathan Corcoran, Advent Venture Partners launched CoCo Therapeutics Ltd. to develop his retinoic acid receptor alpha (RARA) agonists to treat Alzheimer's disease.

Corcoran is director of the Neuroscience Drug Discovery Unit at King's College London. In February, his group published in the European Journal of Neurosciencethat RARA agonists can clear and counteract the toxic effects of beta amyloid and prevent tau phosphorylation in a mouse model of AD...